Source: Eur Respir J 2009; 33: 717-721



Rating:

Share or cite this content

Citations should be made in the following way:
Michelakis E. D.. Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern. Eur Respir J 2009; 33: 717-721

Member's Comments

No comment yet.

Related content which might interest you: Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009 First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Source: Eur Respir J 2009; 33: 785-792 Year: 2009 Soluble guanylyl cyclase expression is reduced in acute lung injury Source: Eur Respir J 2006; 28: Suppl. 50, 398s Year: 2006 Soluble guanylate cyclase stimulators revert in vitro cigarette smoke effects through JNK pathway normalization Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Resistive breathing reduces soluble guanylyl cyclase expression Source: Annual Congress 2009 - Cell biology of lung disease Year: 2009 New drugs for pulmonary hypertension Source: Eur Respir Mon 2012; 57: 233-246 Year: 2012 Molecular mechanisms involved in the therapeutic action of the stimulation of soluble guanylate cyclase (sGC) in an experimental model of guinea pig exposed to cigarette smoke Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling Year: 2019 Down-regulation of soluble guanylyl cyclase in asthma contributes to airway hyperreactivity Source: Eur Respir J 2005; 26: Suppl. 49, 581s Year: 2005 Effects of a soluble guanylate cyclase stimulator, BAY 41-8543, upon right ventricular function in experimental pulmonary embolism Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 The stimulator of soluble guanylate cyclase riociguat protects against bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Source: Eur Respir Rev 2007; 16: 105-112 Year: 2007 The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Effects of soluble guanylate cyclase (sGC) stimulation in guinea pigs chronically exposed to cigarette smoke Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012 The role of guanylyl cyclase in resistive breathing Source: Annual Congress 2013 –Experimental models in critical care Year: 2013 Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008 Soluble guanylate cyclase stimulator riociguat prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Source: Annual Congress 2011 - Translational models of disease Year: 2011 Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Source: Eur Respir Rev 2009; 19: 68-71 Year: 2010 A soluble guanylate cyclase stimulator, BAY 41-8543, preserves pulmonary artery endothelial function in experimental pulmonary embolism Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014